The document discusses Glaukos Corporation's efforts to develop micro-scale injectable therapies for treating glaucoma, including its iDose Travoprost implant. Preliminary results from a Phase II clinical trial of iDose Travoprost show average intraocular pressure reductions of 7.9-8.5 mmHg (32-33%) at 12 months, comparable to topical timolol. Patients using the implant also had lower average medication needs of 0.54 medications at 12 months. The implant aims to provide at least 6 months of intraocular pressure control with fewer side effects than eye drops to improve adherence to glaucoma treatment regimens.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' micro-invasive glaucoma surgery technology and pipeline of micro-scale injectable therapies to treat the full spectrum of glaucoma disease. Key highlights include Glaukos' financial performance since its IPO, with over $300,000 iStents implanted globally and commercial sales in 15 countries. The document also provides details on iDose, an investigational travoprost drug delivery implant designed to continuously deliver medication directly into the eye over multiple years.
The document summarizes Glaukos Corporation's solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery (MIGS) device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then describes their vision to transform glaucoma treatment through MIGS technologies and sustained drug delivery therapies. This includes a drug-eluting implant to provide extended drug therapy and algorithms to optimize treatment based on disease severity.
The document discusses Glaukos' solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then introduces their vision to transform glaucoma treatment through micro-invasive surgical and pharmaceutical therapies, including a drug delivery implant to provide sustained drug therapy.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
This document provides a summary of key information from a Glaukos Corporation presentation:
- Glaukos is transforming glaucoma therapy through micro-scale injectable therapies like iStent that restore and enhance the eye's natural drainage system.
- Clinical trials show iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years while reducing medication needs by over 80%.
- US retrospective studies of over 100 eyes found iStent with cataract surgery lowered pressure 22% and medications 56% at 2 years.
- An international study demonstrated iStent's pressure lowering ability increases with 1, 2, or 3 stents implanted as a standalone procedure.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
The document discusses Glaukos Corporation's portfolio of micro-scale injectable glaucoma therapies and products in development. It summarizes key 2017 accomplishments including clinical trials, new product submissions, and international expansion. The document outlines Glaukos' vision to address the full range of glaucoma disease states with novel surgical and pharmaceutical therapies, highlighting the iDose travoprost intraocular drug delivery implant currently in Phase II clinical trials. Glaukos aims to deliver five new U.S. product introductions between 2018-2023 to transform glaucoma treatment.
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' micro-invasive glaucoma surgery technology and pipeline of micro-scale injectable therapies to treat the full spectrum of glaucoma disease. Key highlights include Glaukos' financial performance since its IPO, with over $300,000 iStents implanted globally and commercial sales in 15 countries. The document also provides details on iDose, an investigational travoprost drug delivery implant designed to continuously deliver medication directly into the eye over multiple years.
The document summarizes Glaukos Corporation's solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery (MIGS) device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then describes their vision to transform glaucoma treatment through MIGS technologies and sustained drug delivery therapies. This includes a drug-eluting implant to provide extended drug therapy and algorithms to optimize treatment based on disease severity.
The document discusses Glaukos' solutions portfolio for treating glaucoma. It outlines their current micro-invasive glaucoma surgery device, the iStent, and clinical data showing sustained IOP reduction and medication reduction. It then introduces their vision to transform glaucoma treatment through micro-invasive surgical and pharmaceutical therapies, including a drug delivery implant to provide sustained drug therapy.
Glaukos investor presentation updated as of 11282016 for website posstingglaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes minimally-invasive micro-scale injectable therapies to restore and enhance the eye's natural drainage system including the iStent, iStent Inject, and iStent Supra. Clinical trials demonstrate that a single iStent used in combination with cataract surgery achieves significant and sustained reductions in eye pressure and medication use through three years.
This document provides a summary of key information from a Glaukos Corporation presentation:
- Glaukos is transforming glaucoma therapy through micro-scale injectable therapies like iStent that restore and enhance the eye's natural drainage system.
- Clinical trials show iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years while reducing medication needs by over 80%.
- US retrospective studies of over 100 eyes found iStent with cataract surgery lowered pressure 22% and medications 56% at 2 years.
- An international study demonstrated iStent's pressure lowering ability increases with 1, 2, or 3 stents implanted as a standalone procedure.
Glaukos investor presentation for q2 2017 for website and 8_kglaukos
This document discusses Glaukos Corporation and its glaucoma treatment technologies. It contains the following key points:
- Glaukos is transforming glaucoma therapy with micro-scale injectable treatments that restore eye's natural drainage and reduce intraocular pressure, the only proven treatment for glaucoma.
- Their flagship product, iStent, is a single-use micro-bypass stent that has demonstrated long-term IOP reduction and medication reduction when used with cataract surgery based on multiple clinical studies.
- New products in development include iStent Inject for combination cataract/glaucoma procedures, iStent Supra to access a secondary drainage pathway, and iDose for targeted
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
The Point of Care Diagnostics Market 2014-2024Visiongain
This document provides an overview and market analysis of the point of care diagnostics market from 2014 to 2024. It discusses key segments of the market such as blood glucose testing, coagulation testing, cardiac marker testing, and infectious disease testing. It also profiles the leading companies in the point of care diagnostics market, including Roche, Abbott, Siemens, and Alere. The document contains sales forecasts for the global point of care diagnostics market and various regional markets from 2014 to 2024. It identifies factors driving growth in the point of care diagnostics field as well as challenges faced by new entrants.
Karl-Ludwig Kley, CEO and Marcus Kuhnert, CFO held Merck's annual press conference on March 8, 2016 to report on the company's financial results for 2015. Merck achieved stronger results in 2015 with net sales increasing 7.1% to €12.8 billion and EBITDA pre growing 13% to €3.6 billion. All business segments saw organic sales growth with particularly strong growth in Asia-Pacific, Latin America, and the Middle East and Africa. Merck also successfully integrated the Sigma-Aldrich acquisition which closed in November 2015. Looking ahead, Merck expects continued growth driven by its existing businesses and progress in its pipeline.
Merck reported strong financial results for fiscal year 2016. Net sales increased 17% to €15.02 billion, driven by organic growth across all regions and the acquisition of Sigma-Aldrich. EBITDA pre increased 24% to €4.49 billion and EPS pre increased 28% to €6.21, both exceeding guidance. All business sectors achieved organic growth, with particularly strong contributions from the Life Science and Healthcare sectors. Merck also reduced net financial debt by 9% and proposed a dividend of €1.20 per share, a 19% increase over the prior year.
Udit Batra, CEO of Life Science at Merck KGaA, presented at the UBS Global Healthcare Conference in New York on May 23, 2016. Merck KGaA is a leader in the life science industry with a portfolio of three high-tech businesses: Life Science, Performance Materials, and Healthcare. The integration of the Sigma-Aldrich acquisition is on track to deliver cost synergies while maintaining sales momentum in the Life Science business. Merck KGaA expects mid-single digit organic growth in Life Science in 2016, driven primarily by the Process Solutions business unit.
The FOURIER trial investigated whether adding evolocumab to statin therapy reduces cardiovascular events. Over 27,000 patients with a history of cardiovascular disease were randomized to receive evolocumab or placebo injections in addition to statin therapy. The primary objective was to determine if evolocumab lowered the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death. Secondary objectives were to examine the long-term safety and tolerability of evolocumab and investigate the efficacy and safety of achieving very low LDL-cholesterol levels. Results from this outcomes trial could provide evidence on whether PCSK9 inhibition translates to clinical benefit for high-risk patients.
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Amgen Inc. is a biotechnology/pharmaceutical company based in the US that was founded in 1980. The document provides an overview of Amgen's financial performance, acquisitions, competitors including AbbVie, Johnson & Johnson, and Celgene, and recommends Amgen as a moderately safe investment option in the biotech industry.
Ethocle Reports has published its latest Market Research Report on Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
This document provides an overview and market analysis of the global ophthalmic drugs market from 2015 to 2025. It discusses key segments such as retinal disorders, glaucoma, dry eye, and allergic/inflammatory drugs. The market is led by drugs for retinal disorders including Lucentis, Eylea, and Avastin. The US is the largest market, followed by key regions in Europe and Asia. Leading companies discussed are Novartis, Allergan, Roche, and Pfizer. The market is expected to grow due to an aging population and increasing prevalence of eye diseases.
Sweden Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multiparam...ReportsnReports
This report provides an in-depth analysis of the Sweden patient monitoring market from 2004-2018. It covers market size, segmentation, trends and forecasts for major categories such as fetal monitors, multiparameter monitoring, neonatal monitors, and others. It also profiles the key players and provides company shares. Major players analyzed include Philips, Draeger, GE Healthcare, Omron and Mindray. The 172-page report is available for purchase for $2,500 and offers comprehensive data to develop business and market strategies in the Sweden patient monitoring space.
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
New Zealand Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multi...ReportsnReports
This report provides an in-depth analysis of the patient monitoring market in New Zealand from 2004-2018. It is segmented into fetal monitors, multiparameter patient monitoring, neonatal monitors, non-invasive blood pressure monitors, patient monitoring accessories, and remote patient monitoring. For each segment, the report provides historical and projected market size, volume, and average price data. It also includes company share and distribution share data. Key players in the New Zealand patient monitoring market are analyzed. The 183-page report can be purchased for a single-user license of $2,500.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
Glaukos investor presentation for web march 2017glaukos
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies. It summarizes Glaukos' 2016 accomplishments including strong sales growth and clinical trial progress. The document also summarizes clinical data showing the intraocular pressure and medication lowering capabilities of Glaukos' iStent technology. Finally, it outlines Glaukos' strategies to establish minimally invasive glaucoma surgery as the standard of care for treating open-angle glaucoma.
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies:
- Glaukos has demonstrated strong revenue growth and profitability through the successful launch of its iStent device, which transforms glaucoma treatment from eye drops to a micro-invasive surgical procedure.
- The global glaucoma treatment market is large and growing due to an aging population, and current eye drop treatments have significant drawbacks.
- Glaukos is developing an advanced portfolio of micro-scale injectable therapies including the iStent Inject, iStent Supra, and iDose to treat glaucoma at different stages of progression and reduce dependency on eye drops.
- Clinical studies show
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...IMARC Group
The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2027, exhibiting a growth rate (CAGR) of 6.52% during 2022-2027.
More Info:- https://www.imarcgroup.com/glaucoma-therapeutics-market
Impax third quarter 2017 earnings call presentation impax-labs
Impax reported third quarter 2017 results and provided a business update. Key points include:
- Revenues declined year-over-year due to lower generic pricing, but increased sequentially driven by cost savings initiatives. Adjusted EBITDA and EPS also increased quarter-over-quarter.
- Generic division revenues declined year-over-year due to lower pricing, partially offset by higher volumes. Pricing declines moderated sequentially. The specialty pharmaceutical division saw revenue growth driven by higher product sales.
- Phase 2b results for Parkinson's treatment IPX203 showed significant reduction in "off time" compared to an immediate-release competitor, supporting advancement to Phase 3.
- Impax remains on track or ahead of
The Point of Care Diagnostics Market 2014-2024Visiongain
This document provides an overview and market analysis of the point of care diagnostics market from 2014 to 2024. It discusses key segments of the market such as blood glucose testing, coagulation testing, cardiac marker testing, and infectious disease testing. It also profiles the leading companies in the point of care diagnostics market, including Roche, Abbott, Siemens, and Alere. The document contains sales forecasts for the global point of care diagnostics market and various regional markets from 2014 to 2024. It identifies factors driving growth in the point of care diagnostics field as well as challenges faced by new entrants.
Karl-Ludwig Kley, CEO and Marcus Kuhnert, CFO held Merck's annual press conference on March 8, 2016 to report on the company's financial results for 2015. Merck achieved stronger results in 2015 with net sales increasing 7.1% to €12.8 billion and EBITDA pre growing 13% to €3.6 billion. All business segments saw organic sales growth with particularly strong growth in Asia-Pacific, Latin America, and the Middle East and Africa. Merck also successfully integrated the Sigma-Aldrich acquisition which closed in November 2015. Looking ahead, Merck expects continued growth driven by its existing businesses and progress in its pipeline.
Merck reported strong financial results for fiscal year 2016. Net sales increased 17% to €15.02 billion, driven by organic growth across all regions and the acquisition of Sigma-Aldrich. EBITDA pre increased 24% to €4.49 billion and EPS pre increased 28% to €6.21, both exceeding guidance. All business sectors achieved organic growth, with particularly strong contributions from the Life Science and Healthcare sectors. Merck also reduced net financial debt by 9% and proposed a dividend of €1.20 per share, a 19% increase over the prior year.
Udit Batra, CEO of Life Science at Merck KGaA, presented at the UBS Global Healthcare Conference in New York on May 23, 2016. Merck KGaA is a leader in the life science industry with a portfolio of three high-tech businesses: Life Science, Performance Materials, and Healthcare. The integration of the Sigma-Aldrich acquisition is on track to deliver cost synergies while maintaining sales momentum in the Life Science business. Merck KGaA expects mid-single digit organic growth in Life Science in 2016, driven primarily by the Process Solutions business unit.
The FOURIER trial investigated whether adding evolocumab to statin therapy reduces cardiovascular events. Over 27,000 patients with a history of cardiovascular disease were randomized to receive evolocumab or placebo injections in addition to statin therapy. The primary objective was to determine if evolocumab lowered the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death. Secondary objectives were to examine the long-term safety and tolerability of evolocumab and investigate the efficacy and safety of achieving very low LDL-cholesterol levels. Results from this outcomes trial could provide evidence on whether PCSK9 inhibition translates to clinical benefit for high-risk patients.
Pharma Leader Series Top 25 Ophthalmic Drug Manufacturers 2015-2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1404/Pharma-Leader-Series-Top-25-Ophthalmic-Drug-Manufacturers-2015-2025
Amgen Inc. is a biotechnology/pharmaceutical company based in the US that was founded in 1980. The document provides an overview of Amgen's financial performance, acquisitions, competitors including AbbVie, Johnson & Johnson, and Celgene, and recommends Amgen as a moderately safe investment option in the biotech industry.
Ethocle Reports has published its latest Market Research Report on Transdermal Drug Delivery - Medical Devices Pipeline Assessment, 2016. Formulate significant competitor information, analysis, and insights to improve R&D strategies. Browse market data tables and figures.
This document provides an overview and market analysis of the global ophthalmic drugs market from 2015 to 2025. It discusses key segments such as retinal disorders, glaucoma, dry eye, and allergic/inflammatory drugs. The market is led by drugs for retinal disorders including Lucentis, Eylea, and Avastin. The US is the largest market, followed by key regions in Europe and Asia. Leading companies discussed are Novartis, Allergan, Roche, and Pfizer. The market is expected to grow due to an aging population and increasing prevalence of eye diseases.
Sweden Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multiparam...ReportsnReports
This report provides an in-depth analysis of the Sweden patient monitoring market from 2004-2018. It covers market size, segmentation, trends and forecasts for major categories such as fetal monitors, multiparameter monitoring, neonatal monitors, and others. It also profiles the key players and provides company shares. Major players analyzed include Philips, Draeger, GE Healthcare, Omron and Mindray. The 172-page report is available for purchase for $2,500 and offers comprehensive data to develop business and market strategies in the Sweden patient monitoring space.
Art 1236 rev c-valeritas investor deck 2.0_final_080618 web versionvaleritasir
Valeritas is a medical technology company focused on improving health and simplifying life for people with diabetes. Their flagship product, V-Go, is a wearable insulin delivery device for patients with type 2 diabetes. The presentation discusses Valeritas' significant market opportunity in the global diabetes pandemic, validates their new high-touch sales model which is driving accelerating revenue growth, and presents their attractive financial profile and path to profitability. Key risks to their projections include reliance on V-Go for revenue, ability to retain customers and achieve market acceptance, and manufacturing risks.
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
New Zealand Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Multi...ReportsnReports
This report provides an in-depth analysis of the patient monitoring market in New Zealand from 2004-2018. It is segmented into fetal monitors, multiparameter patient monitoring, neonatal monitors, non-invasive blood pressure monitors, patient monitoring accessories, and remote patient monitoring. For each segment, the report provides historical and projected market size, volume, and average price data. It also includes company share and distribution share data. Key players in the New Zealand patient monitoring market are analyzed. The 183-page report can be purchased for a single-user license of $2,500.
Glaukos march 2018 ir presentation 03012018glaukos
The document discusses Glaukos Corporation, a medical technology company focused on glaucoma treatment. It provides an overview of Glaukos' product portfolio including the iStent, pipeline of micro-scale injectable therapies like iStent inject and iDose travoprost implant. It summarizes Glaukos' 2017 financial and operational performance including revenue growth, expansion into new markets, and progress advancing its product pipeline. The document positions Glaukos to address the full range of glaucoma disease states with its portfolio of MIGS and beyond therapies.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
Glaukos investor presentation for web march 2017glaukos
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies. It summarizes Glaukos' 2016 accomplishments including strong sales growth and clinical trial progress. The document also summarizes clinical data showing the intraocular pressure and medication lowering capabilities of Glaukos' iStent technology. Finally, it outlines Glaukos' strategies to establish minimally invasive glaucoma surgery as the standard of care for treating open-angle glaucoma.
This document provides an overview of Glaukos Corporation and its glaucoma treatment technologies:
- Glaukos has demonstrated strong revenue growth and profitability through the successful launch of its iStent device, which transforms glaucoma treatment from eye drops to a micro-invasive surgical procedure.
- The global glaucoma treatment market is large and growing due to an aging population, and current eye drop treatments have significant drawbacks.
- Glaukos is developing an advanced portfolio of micro-scale injectable therapies including the iStent Inject, iStent Supra, and iDose to treat glaucoma at different stages of progression and reduce dependency on eye drops.
- Clinical studies show
Glaucoma Therapeutics Market Growth, Demand and Challenges of the Key Industr...IMARC Group
The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2027, exhibiting a growth rate (CAGR) of 6.52% during 2022-2027.
More Info:- https://www.imarcgroup.com/glaucoma-therapeutics-market
Impax third quarter 2017 earnings call presentation impax-labs
Impax reported third quarter 2017 results and provided a business update. Key points include:
- Revenues declined year-over-year due to lower generic pricing, but increased sequentially driven by cost savings initiatives. Adjusted EBITDA and EPS also increased quarter-over-quarter.
- Generic division revenues declined year-over-year due to lower pricing, partially offset by higher volumes. Pricing declines moderated sequentially. The specialty pharmaceutical division saw revenue growth driven by higher product sales.
- Phase 2b results for Parkinson's treatment IPX203 showed significant reduction in "off time" compared to an immediate-release competitor, supporting advancement to Phase 3.
- Impax remains on track or ahead of
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
- Frexalimab demonstrated significantly reduced disease activity in relapsing multiple sclerosis in a phase 2 trial, meeting its primary endpoint with an 89% reduction in new gadolinium-enhancing lesions. It was well tolerated across all dose arms. Pivotal trials are planned to start in 2024.
- Amlitelimab showed statistically significant improvements in atopic dermatitis symptoms compared to placebo in a phase 2b trial. Biomarker results support effects on both type 2 and non-type 2 inflammation pathways. It was well tolerated. Pivotal trials are planned for 2024.
- A phase 1b trial of SAR443765, an IL-13/TSL
- Sanofi reported Q2 2023 results with total sales up 3.3% driven by double-digit growth of Specialty Care led by Dupixent and strong growth in Vaccines, while CHC was impacted by a Q1 inventory build.
- Specialty Care sales increased 11.8% led by 34.2% growth of Dupixent which saw demand-driven growth across its five approved indications. Rare Diseases grew 9.6% mainly due to patient accruals in Fabry and Pompe franchises and the strong launch of Nexviazyme. Neurology, Oncology and Rheumatology declined 35.1% due to LOE impact on Aubagio.
-
Nemaura Medical (NASDAQ: NMRD)
Nemaura Medical (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetic
Amgen Cowen and Company 37th Annual Health Care Conference PresentationThe ScientifiK
This document summarizes an oral presentation given by David Meline, Executive Vice President and Chief Financial Officer of Amgen, at the Cowen and Company 37th Annual Health Care Conference on March 8, 2017. The presentation discusses Amgen's strong financial and operational execution in 2016, advancement of its innovative pipeline including positive cardiovascular outcomes data for Repatha, and growth opportunities across therapeutic areas like oncology, neuroscience, and bone health. It also reviews Amgen's biosimilars portfolio and strategy to invest in external innovation and deliver significant returns to shareholders through dividends and share repurchases.
Pharmacovigilance Market PPT 2022: Size, Growth, Demand and Forecast till 2027IMARC Group
The global pharmacovigilance market size reached US$ 6.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2027, exhibiting a CAGR of 10.5% during 2022-2027.
More Info:- https://www.imarcgroup.com/pharmacovigilance-market
Continuous Glucose Monitoring Systems Market PPT 2023: Size, Growth, Demand a...IMARC Group
The global continuous glucose monitoring systems market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 5.7% during 2023-2028.
More Info:- https://www.imarcgroup.com/continuous-glucose-monitoring-systems-market
This document provides a summary and market analysis of potential vaccines to treat opioid use disorder (OUD). It contains a 140-slide presentation and accompanying Excel workbook forecasting the potential market size and revenues for OUD vaccines in major western markets through 2045 under three scenarios. The document reviews the global OUD epidemic, current treatments, prevention strategies, vaccine technologies in development, and competitive landscape. It models vaccine uptake, pricing, and revenues to inform those seeking to understand the business potential for an OUD vaccine.
Peptide Therapeutics Market by Product Type, Distribution Channel, End User 2...IMARC Group
The global peptide therapeutics market reached a value of US$ 35.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 61.9 Billion by 2027, exhibiting a CAGR of 9.42% during 2022-2027.
More Info:- https://www.imarcgroup.com/peptide-therapeutics-market
The document is an investor presentation by Antares Pharma discussing its business and growth strategy. It summarizes that Antares has a diversified revenue mix from proprietary, partner, and development products. It achieved $184 million in revenue in 2021 and guides to $200-220 million in 2022. It is focusing on urology and endocrinology areas with innovative products like XYOSTED and NOCDURNA. XYOSTED is an once weekly testosterone injection that has seen growing prescription trends. The presentation outlines Antares' strategy to expand partnerships and its proprietary product portfolio to drive continued financial growth.
Companion Diagnostics Market PPT: Growth, Outlook, Demand, Keyplayer Analysis...IMARC Group
The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027.
More Info:- https://www.imarcgroup.com/companion-diagnostics-market
12 05 08 deutsche bank healthcare conference supporting materialsThe ScientifiK
Amgen provided an overview of its business and pipeline at the 37th Annual Health Care Conference on May 8, 2012. Key points included: Amgen started 2012 strongly with record revenues and earnings; growth drivers included Neulasta, Enbrel, XGEVA, and Prolia; the ESA business now represents a smaller proportion of sales; pipeline programs like AMG 145 and AMG 785 are advancing; and recent partnerships and acquisitions have enhanced the pipeline and international business. Amgen reiterated forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from projections.
This document provides an analysis of GlaxoSmithKline's (GSK) financial statements and business strategy. It first examines the pharmaceutical industry and GSK's competitive strategy of differentiation through heavy investment in research and development. It then reviews GSK's annual reports and accounting practices. Finally, it analyzes GSK's profitability ratios from 2009-2013, finding generally declining gross profit margins but increasing net profit margins over time.
Similar to Glaukos may 2018 ir presentation 05152018 (20)
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUESWilliamRodrigues148
Mutual funds are investment vehicles that pool money from multiple investors to purchase a diversified portfolio of stocks, bonds, or other securities. They are managed by professional portfolio managers or investment companies who make investment decisions on behalf of the fund's investors.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.